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This retrospective study aimed to evaluate, through an ad hoc 17-item tool, the Pulmonary Rehabilitation Decisional Score (PRDS),
the priority access to PR prescription by respiratory specialists. The PRDS, scoring functional, clinical, disability, frailty, and
participation parameters from 0 = low priority to 34 = very high priority for PR access, was retrospectively calculated on 124
specialist reports sent to the GP of subjects (aged 71±11 years, FEV1% 51±17) consecutively admitted to our respiratory outpatient
clinic. From the specialist’s report the final subject’s allocation could be low priority (LP) (>60 days), high priority (HP) (30–60
days), or very high priority (VHP) (<30 days) to rehabilitation. The PRDS calculation showed scores significantly higher in VHP
versus LP (𝑝 < 0.001) and significantly different between HP and VHP (𝑝 < 0.001). Comparing the specialist’s allocation decision
and priority choice based on PRDS cut-offs, PR prescription was significantly more appropriate in VHP than in HP (𝑝 = 0.016).
Specialists underprescribed PR in 49% of LP cases and overprescribed it in 46% and 30% of the HP and VHP prescriptions,
respectively. Amulticomprehensive score is feasible being useful for staging the clinical priorities for PR prescription and facilitating
sustainability of the health system.
1. Introduction
Pulmonary rehabilitation (PR) is now an accepted therapy
for subjects with respiratory diseases. Its effectiveness is
supported by numerous randomized controlled trials. Over
the past 30–40 years, PR has evolved from a medical “art”
to evidence-based therapy. Several reviews have summarized
the evidence for PR [1–4]. From these, the ideal candidate
for rehabilitation that emerges is a symptomatic subject with
impaired functional status, low participation in activities of
daily living (ADLs), and low health-related quality of life
(HRQoL), who is a high consumer of healthcare resources
and suffering from the systemic (i.e., nonrespiratory) conse-
quences of chronic obstructive pulmonary disease (COPD)
[1–5]. Beneficial effects of PR have been demonstrated both
in moderate-severe [6–8] and in very mild COPD [9, 10],
although a weak recommendation for a routinely PR in the
latter has been proposed [11]. Previous research showed also
that patients with worse function and health status were the
best responders to rehabilitation [6–8].The positive results of
PR are independent of other factors such as age, gender, and
smoking status, which are not determinants in predicting the
rehabilitation outcome [5].
Otherwise, the current guidelines on PR [1–4] are mainly
based on the experience of the programs provided to outpa-
tients and do not offer any multifaceted tool to determine the
clear indication for priority of PR prescription. Furthermore,
in the current period of economic contraction, health payer
needs instruments to define a “priority setting” and “budget
impact” to cover costs of PR in order to ensure a better
distribution of health resources because we need solid solid
instruments and outcomes to decide how to optimally invest
money in this field [12, 13].
Clinicians really need to be able to define the priority of
PR prescription based on objective and measurable parame-
ters of disease, such as respiratory function, disability, non-
participation in ADLs, and the complexity of their condition.
The development of a dedicated tool could give specialists,
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general practitioners (GPs), and healthcare providers a com-
mon language for both clinical and administrative purposes,
enabling them to prioritize PR access.
The aim of this retrospective study was to evaluate (by
means of a new tool: Pulmonary Rehabilitation Decisional
Score [PRDS], created ad hoc), the appropriateness of priority
of PR prescription proposed by specialists in COPD subjects
referred to the respiratory outpatients clinic.
2. Methods
This study consisted in the development of an assessment
decisional tool (PRDS) filled in “a posteriori” by the specialist
after the outpatients visit to verify the appropriateness of his
decision on priority to PR access.The studywas retrospective,
approved by our local Scientific Board (CTS 24/11/2015) and
by Fondazione S. Maugeri IRCCS Ethics Committee (EC#
2017).
2.1. Development of the Pulmonary Respiratory Decisional
Score (PRDS). To reach face validity based on expert opinion
involving a structured process of consensus, we enrolled
key stakeholders (doctors, nurses, and physiotherapists) from
among health staff employed in the rehabilitation field of our
Institute. They were invited to participate because their skills
and views were considered important. Their participation
involved three focus group meetings over a 1-month period.
Consent was assumed by the agreement to participate.
Step 1. We performed a systematic review of the PR literature
for COPD identifying patients with specific characteristics
and who respond well to PR and prepared a preliminary draft
(PRDS) of a priority PR prescription based on a scoring of
different items and “cut-offs.”
We created two separate focus groups (Groups 1 and
2), each composed of 3 pulmonologists, 3 physiotherapists,
and 2 nurses. The focus group participants were randomly
allocated toGroup 1 orGroup 2.During the firstmeetingwith
separated groups, using aDelphi-like procedure, experts were
asked to rate the importance of carefully preselected items
in the PRDS score on a 5-point Likert scale (0 = absolutely
not important; 1 = not important; 2 = minimally important; 3
= important; 4 = very important). Focus group participants
were also asked to rank the importance of each item on a
scale according to 3 different severity weights for PR priority
indication (from 0 = minimum to 2 = maximum priority
indication for PR). In general the focus group graded items
on the literature’s evidence that more severe and disabled
patients are more likely to respond to PR. Consensus was
considered when more than 75% of the respondents (a) rated
each item as mandatory to be inserted in the score when
considered “important” or “very important” and (b) agreed
to each item’s grading from 0 = minimum to 2 = maximum
priority indication for PR.
Step 2. Group 1 and Group 2 received a preliminary feedback
by each coordinator (MV, MB) on results of step 1 only rela-
tively to their own group.Then, a combinedmeeting between
Groups 1 and 2was performed. At this combinedmeeting, the
two focus groups together had the task to do the following:
(a) share, compare, confirm, or modify the items and scores
proposed, adding any items they felt should be included in the
core set which were not on the initial list provided; (b) verify
that the items were simple, clear, and comprehensible and if
necessary, change them. In particular, focus group discussed
if had to have a higher priority for PR referral for smokers
with respect to no smoking patients, patients with a worse
FEV1, patients with severely limited ADL, older patients
with respect to younger patients. Focus groups discussed the
modality to measure depression/anxiety: in this case groups
have preferred to avoid cumbersome questionnaire referring
solely to the existing description. Discussion was performed
on self-reported adherence to medication/LTOT and self-
reported physical activity and on the most appropriate test
to measure effort tolerance as 6MWD. Agreement between
groups’ members was to propose simple information found
during a normal face-to-face visit or using previous medical
history information so that any operator could easily calculate
the new score. In detail, focus group agreed that smoking
status is not an exclusion criterion for rehabilitation programs
grading this condition more severe than condition of no
smoking. Focus group agreed that smoking subjects were the
ideal population to invest for behavioral changes in lifestyles
offering, at least 1 time in their life, an opportunity to cut
the vicious circle related to smoking with a structured educa-
tional, psychological, and drug program to quit smoking.The
decision to include smoking subjects has been reinforced by
our recent experience on smoking as negative predictor for
exacerbation [14].
Exacerbation was defined as “an event requiring antibi-
otics and/or oral steroids as prescribed by specialist or
patient’s GP” [15] according to GOLD guidelines [16].
Focus group decided to use the number of comorbidities
rather than more sophisticated comorbidities score to speed
the score report; focus group also decided to grade cardiac
and neurological comorbidities in terms of “disability to
exercise” as more disabling ones when compared to other
comorbidities.
Physical activity profile was obtained by a self-reported
answer: “During the last month how much time have you
spent weekly for vigorous ormoderate activities as gardening,
cycling, carrying loads, walking, swimming, performing
daily home activity without any kind of help?” Focus group
decided that the 6MWT value scheduled was that performed
at the time of specialist’s visit or the earlier available in the 6
months preceding the specialist’s visit.
After discussion in this combined meeting, preliminary
conclusions between groups as a whole were reached.
Step 3. Afinal plenary consensusmeeting was held to present
the results from the triage, discuss the measures for the
core set, and approve the definitive version of the tool.
Final consensus was considered when more than 75% of the
respondents rated the PRDS triage acceptable.
The score was thought to be calculated during a specialist
visit or assigned to a case manager (nurse or PT) before the
medical visit. The time to fill all the items is approximately 5
minutes and the final score is automatically calculated by a
dedicated sheet in the Excel program.
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2.2. Measurements. Data were retrieved from specialist
reports compiled at the outpatients visit using (when nec-
essary) hospital report of respiratory functional status and
exercise tolerance sent to the GP.
The following data were collected: anthropometrics as
age, sex, body mass index (BMI), and smoking status;
definitive diagnosis of COPD according to spirometry; clin-
ical status in the previous 6 months (exacerbations and
hospitalization), wellbeing or presence of pain; presence of
comorbidities; arterial pulsed oximetry (oxygen saturation);
present/past data on forced expiratory volume at first second
[FEV1 (% pred.)] and forced vital capacity [FVC (% pred.)];
dyspnea level measured by the Medical Research Council
(MRC) dyspnea scale [17] and disease impact measured by
the COPD Assessment Tool (CAT) [18]; weekly physical
activity; present/past exercise tolerance measured by the
6-minute walking test (6MWT) [19]; ADL participation;
therapy and adherence to treatment; anxiety and depression
status; frailty condition with level of care need.
These data were used to retrospectively calculate the
PRDS score, which was then compared with the PR priority
prescription made by the specialist in the report, as follows:
according to our actual regional suggestions (i.e., Lombardy
region) low priority (LP) for rehabilitation was defined as PR
available over 60 days, high priority (HP) for rehabilitation
available within 30–60 days, and very high priority (VHP)
for rehabilitation available within 30 days. The PRDS score
ranged from 0 = minimum value to 34 = maximum value for
priority of PR access.
2.3. Subjects. All subjects with chronic obstructive pul-
monary disease consecutively referred between 1st January
2016 and 1st March 2016 to the respiratory outpatient clinic
of the Istituti Clinici ScientificiMaugeri—IRCCS, Lumezzane
(BS), Italy—for a second-opinion specialist consultation (first
visit or check-up) were eligible for the study. When admitted
in our institution, the patients received an inpatient program
with an average stay of 25 (SD 3) days with no less than 22
rehabilitative sessions or an outpatient program attending no
less than 22 rehabilitative sessions with 2 or 3 weekly access
instances within a 2-month period. During the entire pro-
gram, interactive and autonomy-supportive approach groups
and paper-copy quit strategy and individually tailored quit
plan with pharmacotherapy guidance were proposed.
Subjects were excluded if any of the following condi-
tions was present: dyspnea at rest with an urgent need of
hospitalization in an acute setting, oncological disease, pain
uncontrolled by medication, terminal illness, neuromuscular
degenerative diseases, severe orthopedic diseases, subject
bedridden or confined to a wheelchair, and altered cognitive
status.
2.4. Statistical Analysis. To define the concept of PR prescrip-
tion (i.e., priority values for LP, HP, and VH), 3 ranges of
PRDS scorewere arbitrarily proposed:≤30%of themaximum
PRDS score range (0–10) identified low priority for PR access
(PR available over 60 days); between 31% and 50% of max.
PRDS score (range 11–17) identified high priority for PR
access (PR available within 30 and 60 days); and >51% (range
18–34) of the maximum PRDS value defined a very high
priority of PR prescription (PR available within 30 days).
PR underprescription was defined by any value outside the
range proper to the relative priority allocation, indicating the
need for a more urgent allocation. PR overprescription was
defined by any value outside the range proper to the relative
priority allocation, indicating the need for a less urgent
allocation.
Normality of the data was tested by the Shapiro-Wilk
test.One-wayANOVAwas performed to compare differences
among settings and if significant, Bonferroni’s multiple com-
parison was applied as post hoc test. Based on the proposed
triage ranges, a test of proportion (test Zeta) was performed
to compare differences in the percentage of appropriate
prescription, underprescription, and overprescription of PR
as decided by the specialist at the outpatient visit. A 𝑝 value
< 0.05 was considered statistically significant.
3. Results
3.1. Development of the PRDS. Thefirst focus group proposed
the following clinical items for the PRDS: functional severity
(FEV1% pred. and FVC % pred.), dyspnea (MRC score),
smoking status, clinical history (exacerbations, hospitaliza-
tions), physical activity (hours/week), disability duringADLs,
wellbeing, depression and anxiety, comorbidities, age, BMI,
frailty (level of care need), and therapy adherence. These
items were proposed as mandatory items for the final score
(Table 1). Three progressive levels of severity (from 0 =
minimal to 2 = maximal priority for PR) were proposed to
grade each item, giving a score range which would represent
conditions of progressively increasing severity and priority
for PR access (Table 1).
The second focus group, after reviewing the proposals,
added two new items (exercise tolerance and disease impact),
modified the questions for depression and anxiety items,
and changed the score weighting for FEV1% pred. and age
items.
A definitive 17-item version of the PRDS was finally
approved (Table 1). The total score ranged from 0 (minimal
priority for rehabilitation) to 34 (maximal priority for reha-
bilitation).
3.2. Retrospective Analysis. One hundred twenty-four outpa-
tient reports (41 indicating LP as a final decision, 37 HP, and
46 VHP) were collected from the hospital database. These
reports were the most recent ones available from subjects
who fulfilled the selection criteria. In 4 out 124 patients the
6MWD was missing. No missing data were recorded for all
other items.
Demographic and clinical characteristics of the study
group are presented in Table 2. The majority of COPD
patients were elderly; many of them were ex-smokers (49%)
or current smokers (19%) with severe lung obstruction,
moderate disease impact, and moderate exercise tolerance.
According to PR priority prescription made by the specialist
in the report (Table 2), very high priority patients were more
elderly, with a worse respiratory function and effort tolerance
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Table 1: Pulmonary Rehabilitation Decisional Score (PRDS).
ITEMS Score
0 1 2
Age, years ≤59 60–74 ≥75
BMI, Kg/m2 21–24 25–30 ≤20 or ≥31
FEV1% pred. ≥65% 36–64% ≤35%
Dyspnea, MRC score (0–4) 0-1 =2 ≥3
6MWT, meters ≥350 ≤349 and ≥250 ≤249
CAT score ≤9 10–15 ≥16
Comorbidities 0 1 1 if cardiac/neurological or >1
Activity of daily life Normal Limited Bedridden/wheelchair-restricted
Severe exacerbations in the last year 0 1 >1
Hospitalizations in the last year 0 0, but 1 ER access >0 or 2 ER access instances
Smoking status Nonsmoker Ex-smoker Current smoker
Physical activity (cyclette, walking, steps) >4 h/week 2–4 h/week <2 h/week
Subjective wellbeing Very well/good Poor bad
Depression No medications Occasional medications Under chronic therapy
Anxiety No medications Occasional medications Under chronic therapy
Care need and availability Not necessary Useful and available full time Useful but available on spot or unavailable
Adherence to medications/oxygen Full Not constant Poor/refusal to comply
FEV1 = forced expiratory volume at first second; MRC =Medical Research Council; ER = emergency room;W = week; BMI = body mass index; CAT = COPD
Assessment Tool; 6MWT = 6-min walking test. Consensus was considered when more than 75% of the respondents (a) rated each item as mandatory to be
inserted in the score when considered “important” and/or “very important” and (b) agreed to each item’s grading from 0 =minimum to 2 =maximum priority
indication for PR. Exacerbation was defined as “an event requiring antibiotics and/or oral steroids as prescribed by specialist or patient’s GP.”
Table 2: Demographic, anthropometric, and functional characteristics of study patients.
Whole LP HP VHP 𝑝
Patients, 𝑛 124 41 37 46
Age, years 71 ± 11 72 ± 12 68 ± 11& 74 ± 8 0.031
Males, 𝑛 73 25 18 30 ns
BMI, Kg/m2 24 ± 3 23 ± 2 25 ± 3$ 24 ± 4 0.0120
Smokers, 𝑛 24 8 7 9 ns
Ex-smokers, 𝑛 61 15 19 27 ns
SatO2, % 94 ± 2 95 ± 2 94 ± 2
∘ 93 ± 2∗ <0.0001
FEV1, % pred. 51 ± 17 57 ± 15 55 ± 16
? 43 ± 17∗ 0.0002
FVC, % pred. 78 ± 23 86 ± 19 85 ± 19∘ 66 ± 23∗ <0.0001
FEV1/FVC% 65 ± 7 65 ± 6 64 ± 9 65 ± 6 ns
CAT, score 14 ± 6 10 ± 4 14 ± 5∧,& 17 ± 6∗ <0.0001
6MWT, meters 321 ± 131 382 ± 144 369 ± 115∘ 228 ± 62∗ <0.0001
LP = low priority; HP = high priority; VHP = very high priority. BMI = body mass index; SatO2 = pulsed arterial saturation; FEV1 = forced expiratory volume
at first second; FVC = forced vital capacity; CAT = COPD Assessment Tool; 6MWT = 6-min walking test. $𝑝 < 0.05, ∧𝑝 < 0.01, and ∗𝑝 < 0.001 versus LP;
&𝑝 < 0.05, ?𝑝 < 0.01, and ∘𝑝 < 0.001 versus VHP.
and presenting higher disease impact when compared to high
and low priority patients.
The PRDS showed a median score of 10 for LP indication,
12 for HP indication, and 20 for VHP indication (Figure 1).
As shown in Figure 1, subjects within each PR indication
group presented a high variability of PRDS, the coefficient
of variation being 51% for LP prescription, 36% for HP, and
20% for VHP. An overlapping of LP and HP prescription was
observed. The PRDS score was similar in LP and HP and
significantly lower than in VHP prescription (𝑝 < 0.001 for
both) (Figure 1).
According to the 3 score ranges for priority PR pre-
scription (LP prescription = PRDS 0–10, HP prescription
= PRDS 11–17, and VHP prescription = PRDS 18–34) the
percentage of subjects who received an adequate priority
prescription, underprescription, or overprescription for PR
was calculated (Figure 2). Adequate priority prescription was
significantly higher (𝑝 = 0.016) in VHP compared to HP
reports; underprescription was significantly higher (𝑝 <
0.0001) in LP compared to VHP reports; overprescription
was significantly higher (𝑝 = 0.014) in HP compared to LP
reports (Figure 2). Of note, specialists at the outpatient visit















Figure 1: PRDS score, calculated on single report at the time of
outpatients visit. Median value indicates the score to be given to
the specialist’s prescription for low priority (LP, circles, 𝑛 = 41);
high priority (HP, triangles, 𝑛 = 37); and very high priority
(VHP, squares, 𝑛 = 46). Dotted lines at 11 and 18 delimit the
arbitrary cut-offs of PR priority, that is, for LP (0–10), HP (11–17),
and VHP (18–34). One-way ANOVA was performed to compare
differences among settings and, where significant, Bonferroni’s
multiple comparison was applied as post hoc test. A 𝑝 value < 0.05
was considered statistically significant.
prescribed low priority rehabilitation (i.e., underestimating
the urgency need) in 49% of cases; of this underprescription
75% concerned subjects who would have required PR within
30–60 days and 25% concerned subjects who would have
needed PR within 30 days. Otherwise, in 11% of cases
specialists prescribed rehabilitation with less urgency than
required. Conversely, PR was overprescribed in 46% of HP
reports and in 30% of VHP reports.
4. Discussion
COPD subjects undergo a gradual decline in respiratory
function and their level of disability increases, driving them
into a phase of high clinical complexity characterized by
repeated exacerbations and hospitalizations. To integrate
the multiple dimensions of care necessary for optimal and
sustained subject benefits, a “chronic disease care” model
[20] has been proposed. PR, with its interdisciplinary patient-
centered approach and its emphasis on partnering, commu-
nication, and coordination among healthcare professionals, is
an excellent platform for the implementation of an integrated
chronic disease care model [5].
The issue of appropriateness and suitability of diag-
nosis, prescription, and care in medicine, particularly in
the rehabilitation field, is increasingly being recognized in
this period of time when health economic resources are
shrinking. For instance, overprescription of PR giving high
or very high priority rather than low priority may cause
inefficiency, economic waste, and an unjust distribution of
health resources.
Future challenges for PR are to find ways to maintain the



































Figure 2: Percentage of adequate prescription (white bars), under-
prescription (row bars), and overprescription (black bars) of PR
rehabilitation in the LP, HP, and VHP groups according to the PRDS
cut-off values proposed (LP: 0–10, HP: 11–17, andVHP: 18–34). A test
of proportion (test Zeta) was performed to compare differences in
the percentage of appropriate prescription, underprescription, and
overprescription of PR as decided by the specialist at the outpatient
visit. A 𝑝 value < 0.05 was considered statistically significant.
of its value, and install a fair reimbursement scheme [21]. A
significant barrier to the effective use of PR in the community
is a lack of awareness among many healthcare providers
of the nature and benefits of rehabilitation. The difficulty
of assessing the real needs of subjects who could benefit
most from PR programs makes it impossible to estimate
the potential inadequacy between nonexpressed demand and
insufficient supply of rehabilitation. As confirmation, the
current volume of days devoted to PR represents only 6%
of the total rehabilitation days reimbursed by the National
Health System in Italy [22]. In real life, evidence of the
poor attitude towards PR prescription in Italy was shown
in a clinical trial [23] in which only 0.11% of the local
population and 2.3%of estimatedCOPD subjects, in one year,
participated in a PR program.
Payment for PR varies widely among healthcare systems
worldwide. Reimbursement may represent a gross area of
underpayment due to underreporting by hospitals of charges
and rehabilitation services required [24] but also a gross
overpayment due to an inappropriate choice of candidates for
PR and of the setting in which to conduct it.
A multidimensional profiling of response to PR might
provide several useful pieces of information, such as the
overall priority of intervention, the type of response in
each single outcome, and suggestions of how to personalize
activities to achieve the goals they perceive as the most
important in their daily life [13].
To promote an adequate level of priority in prescription
of PR programs, there is a logical need for multidimensional
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diagnostic, clinical, and functional tools based on multicom-
prehensive criteria of respiratory function, comorbidities,
disability, and frailty. It is reasonable to believe that the
efficacy of PR is strictly related to a good subject selection,
choosing the patient with the highest potential benefits, and
respecting a priority access list. However, in the real world,
the choice of the more appropriate subject for PR and the
setting in which to conduct PR often depends on funding
schemes, the subject’s willingness to undergo/continue a
program, long waiting lists, socioeconomic reasons, and so
on. Hence, the selection of subjects for PR should not be
based only on the subject’s lung function but rather on a
global assessment of the extrapulmonary consequences of
COPD, proven to be reversible with rehabilitation [5].
The literature suggests that the ideal candidate for reha-
bilitation is a symptomatic subject with impaired functional
status and low participation in ADLs, high utilization of
healthcare resources, and suffering from the systemic conse-
quences of COPD [5].
PR programs have traditionally been developed as out-
patient programs. However, in some Italian regions, PR
programs are frequently offered in an inpatient setting [22].
Inpatient programs are effective but may be expensive and
should thus be reserved perhaps for the more complex
subjects. The proposed PRDS score, based on findings from
the literature and our own clinical experience, classifies
subjects’ clinical severity in terms of functional, disability,
clinical, psychological, behavioral and frailty, criteria, allow-
ing to better allocate health resources proposing a sort of
appropriate priority for PR.
From our data, an adequate PR prescription is clearly
more frequent when the indication is for very high priority.
Underprescription of PR occurs in 19% of subjects referred to
a respiratory specialist (more evident in the group proposed
for the low priority list), while overprescription (25% of the
whole sample) ismore frequent in relation to the high priority
admission.
By indicating the appropriate priority for PR the PRDS
would (a) facilitate PR prescription to subjects who at present
are not given the opportunity and (b) reallocate health costs
respecting the priority of PR access.
4.1. Study Limitations. The retrospective study design, the ad
hoc development of the decisional tree, and the (sometimes)
arbitrary choice for the cut points used, without a prospective
validation cohort, may be limitations.
No specific additional psychometric testing was con-
ducted as specific reliability, construct validity, and sensitivity
and specificity tests.
The outpatient clinic where the study was conducted was
located within a rehabilitation hospital and this fact may
have undermined the generalizability of results. Nevertheless,
we believe that using the PRDS in an in-hospital setting or
GP office could reproduce or elicit the present results. The
wording “adequate prescription” as used in the paper is based
on the scoring and not on quantitative research showing
benefits.
We believe the paper raises the issue of an impor-
tant lack in research, namely, the lack of guidance in the
priority prescription of rehabilitation for all chronic respi-
ratory disease patients as well as guidelines about which
program/setting suit subject profile. As final limitation we
underline that a scoring system, like guidelines, could fall
short of addressing the individual patient unique circum-
stances.
Future studies would establish if actual Pulmonary Reha-
bilitation Decisional Score could be equally useful for na¨ıve
patients or patients with several PR access instances (mainte-
nance rehabilitation).
5. Conclusions
In COPD subjects referred to an outpatient respiratory clinic,
(i) under- and overprescription of PR occurs and (ii) a
new multicomprehensive triage, the Pulmonary Rehabili-
tation Decisional Score, based on lung function, clinical
parameters, disability, frailty, and participation in ADLs, is
feasible and may be useful for staging the clinical priority
of PR prescription, facilitating the preparation of a waiting
list and sustainability of the health system. Future studies
will prospectively validate this new tool looking at internal
consistency of the items when relating to benefits of PR, PR
program completion, comparing triage prescription versus
specialist’s PR prescription.
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Additional Points
What This Paper Contributes to Our Knowledge. Pulmonary
rehabilitation (PR) is now an accepted therapy for subjects
with respiratory diseases. The current guidelines on PR are
mainly based on the experience of the programs provided to
outpatients and do not offer any multifaceted tool to deter-
mine the level of PR priority prescription, for any given sub-
ject. What This Paper Adds. We have proposed an ad hoc 17-
item instrument—the Pulmonary Rehabilitation Decisional
Score (PRDS)—tomeasure the priority appropriateness of PR
prescription. In subjects referred to an outpatient respiratory
clinic under- and overprescription of PR occurs. The PRDS,
based on lung function, clinical parameters, disability, frailty,
and participation in ADLs, is feasible and may be useful for
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staging the clinical priority of PR prescription facilitating
sustainability of the health system.
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